← Back to Search

Behavioural Intervention

Shared Decision Making for Juvenile Arthritis (PERSON-JIA Trial)

N/A

Recruiting

Led By Lori B Tucker, MD

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must have JIA fulfilling International League of Associations for Rheumatology (ILAR) criteria

Patients must not yet be receiving treatment, or have received only Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) or joint injections

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from enrollment to 6 and 12 months

Awards & highlights

PERSON-JIA Trial Summary

This trial is testing whether a discussion between physicians and families, using a computer-generated personalized outcome report, will improve the tailoring of treatment to the child and control of their disease.

Who is the study for?

This trial is for children newly diagnosed with Juvenile Idiopathic Arthritis (JIA), except those with systemic arthritis. They must be diagnosed by a participating pediatric rheumatologist, not yet on treatment or only on NSAIDs/joint injections, and able to complete forms in English or French.Check my eligibility

What is being tested?

The PERSON-JIA Trial tests Shared Decision Making (SDM) using personalized outcome reports to guide treatment discussions between doctors and families of children with JIA. It aims to tailor treatments better and improve disease control through informed decisions.See study design

What are the potential side effects?

Since the intervention involves decision-making rather than medication, there are no direct side effects from drugs being tested. However, choices made after SDM may lead to varying outcomes based on selected treatments.

PERSON-JIA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with juvenile idiopathic arthritis according to ILAR criteria.

Select...

I have only used NSAIDs or had joint injections for my condition.

PERSON-JIA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from enrollment to 6 and 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from enrollment to 6 and 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to 6 and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Disease

Secondary outcome measures

Change in Health Utilities

Change in Parent-Reported Health-Related Quality of Life

Change in Patient-Reported Health-Related Quality of Life

+8 more

PERSON-JIA Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Shared Decision Making (SDM)Experimental Treatment1 Intervention

Physicians will use the PERSON-JIA Report to guide discussions with the newly diagnosed patient and family. The intervention will not dictate the use of specific medications or treatment strategies, only facilitate better informed treatment choices according to patient circumstances. The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis. Discussion is guided by the PERSON-JIA Report, which is generated in real time, on the physician's smart phone. Patients newly-diagnosed with JIA will be consented to both enrollment in the CAPRI Registry and enrollment in the PERSON-JIA trial. Clinic visit and discussion between the physician, patient and family will be facilitated by the PERSON-JIA report to support a shared decision making process. Questionnaires will be collected at enrollment, at the second visit and at 6-month and 12-month follow-up visits.

Group II: Current Best PracticeActive Control1 Intervention

Physicians randomized to this arm will provide current care and treatment decisions with patients will be made in accordance with current best practices. Will not engage in structured shared decision making (SDM) discussion and will not have access to PERSON-JIA Reports. Patients will be consented to enroll in the CAPRI Registry at the clinic visit when they are diagnosed. Registry enrollment will allow collection and input of clinical data into the Registry. Clinic visit and discussion will remain unchanged for physicians, patients and their families. Questionnaires will be collected at enrollment, at the second visit and a 6-month and 12-month follow-up visits.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor

1,418 Previous Clinical Trials

2,466,276 Total Patients Enrolled

The Arthritis Society, CanadaOTHER

24 Previous Clinical Trials

4,780 Total Patients Enrolled

Canadian Institutes of Health Research (CIHR)OTHER_GOV

1,345 Previous Clinical Trials

26,452,725 Total Patients Enrolled

Media Library

Shared Decision Making (SDM) (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05310799 — N/A

Juvenile Idiopathic Arthritis Research Study Groups: Current Best Practice, Shared Decision Making (SDM)

Juvenile Idiopathic Arthritis Clinical Trial 2023: Shared Decision Making (SDM) Highlights & Side Effects. Trial Name: NCT05310799 — N/A

Shared Decision Making (SDM) (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05310799 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must be met in order for a person to qualify for participation in this clinical trial?

"This clinical trial seeks 842 minors between the ages of one and eighteen who suffer from juvenile arthritis. To be eligible, participants must hold a valid license in pediatric rheumatology in Canada; commit to enrolling their newly diagnosed patients with JIA into the Registry; prove they are either fellows-in-training or physicians planning to retire within two years; consent to having personal information included in the CAPRI JIA Registry and participating in PERSON-JIA trials as well as additional questionnaires for assessing decision making; agree to have medical encounters recorded (if randomly selected); fulfill ILAR criteria for JIA diagnosis; provide care for children"

Answered by AI

Are there current opportunities to join the research trial?

"The information on clinicaltrials.gov does not support the recruitment of new candidates for this trial, which was initially published in February 1st 2023 and last updated October 31st 2022. However, there are still 371 medical studies recruiting participants at present."

Answered by AI